Cite
HARVARD Citation
El-Khoueiry, A. et al. (2017). Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 389 (10088), pp. 2492-2502. [Online].